Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose therapy for diffuse large-cell lymphoma in first remission

A R Perry1, A H Goldstone

  • 1University College London Hospitals, UK.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|May 15, 1998
PubMed
Summary

High-dose therapy is not beneficial for all diffuse large-cell lymphoma (DLCL) patients. Research focuses on identifying poor-prognosis DLCL patients for intensified treatment, including high-dose therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digital quantum magnetism on a trapped-ion quantum computer.

Nature·2026
Same author

Multiple-camera defocus imaging of ultracold atomic gases.

Optics express·2021
Same author

Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.

Bone marrow transplantation·2021
Same author

All-optical intrinsic atomic gradiometer with sub-20 fT/cm/√Hz sensitivity in a 22 µT earth-scale magnetic field.

Optics express·2020
Same author

Characterization of noise sources in a microfabricated single-beam zero-field optically-pumped magnetometer.

Journal of applied physics·2019
Same author

The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.

Bone marrow transplantation·2017

Area of Science:

  • Oncology
  • Hematology
  • Clinical Trials

Background:

  • Diffuse large-cell lymphoma (DLCL) has a 50%-60% cure rate with conventional chemotherapy.
  • Indiscriminate use of high-dose therapy as first-line consolidation increases risks without proven benefit for all DLCL patients.

Purpose of the Study:

  • To identify prognostic factors for diffuse large-cell lymphoma (DLCL).
  • To evaluate the role of intensified first-line treatment, including high-dose therapy, for specific DLCL patient subsets.
  • To determine the optimal treatment strategy for different prognostic groups within DLCL.

Main Methods:

  • Standardization of prognostic factors in DLCL patient populations.
  • Ongoing research into novel prognostic markers, including molecular markers.

Related Experiment Videos

  • Multi-center randomized trials assessing treatment intensity for prognostic subsets.

    • Main Results:

    • Conventional chemotherapy cures 50%-60% of diffuse large-cell lymphoma (DLCL) patients.
    • High-dose therapy offers no advantage for the general DLCL population and increases risks.
    • Focus is shifting towards personalized treatment based on prognostic factors.

    Conclusions:

    • High-dose therapy should be reserved for specific, poor-prognosis diffuse large-cell lymphoma (DLCL) patient groups.
    • Further research and clinical trials are essential to refine treatment strategies for DLCL.
    • Identifying prognostic subsets is key to optimizing DLCL patient outcomes and minimizing treatment-related harm.